Drug Research
Alzheon to advance ALZ-801 into Phase II trial in patients with Alzheimer’s disease
Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug development platform...
Drug Research
InnoCore, Allergan to develop new drug delivery products for ophthalmic diseases
Netherland-based injectable drug delivery products producer InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan (AGN), to develop new medicines for ophthalmic diseases. The deal will see the companies expand their existing...
Drug Research
Adimab, Celgene form drug discovery partnership
Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms of the agreement,...
Drug Research
Adimab, Innovent collaborate on discovery, commercialization of antibody-based therapeutic
Adimab and Innovent have collaborated to discover, develop and commercialise an antibody-based therapeutic, using Adimab antibody discovery and optimization platform, against a selected specific target. All initial product development activities such as cell line development,...
Drug Research
Supernus to launch Trokendi extended release formulation to treat epilepsy
Specialty pharmaceutical company Supernus Pharmaceuticals is set to launch once-daily extended release formulation of topiramate, Trokendi XR, to treat epilepsy following the final FDA approval. Approved for use as recommended in the agreed-upon labeling, Trokendi...
Drug Research
Takeda announces availability of type 2 diabetes drugs in US
Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US. The FDA approved medications are indicated as...
Drug Research
Amedra re-launches Adrenaclick to treat anaphylaxis
Amedra Pharmaceuticals has re-launched a single-dose epinephrine auto-injector Adrenaclick for people with increased risk of anaphylaxis in both 0.15mg and 0.30mg strengths. Potentially life-threatening allergic reaction, Anaphylaxis onsets rapidly and may cause severe swelling, breathing...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
